Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Top Cited Papers
Open Access
- 15 April 2000
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 105 (8) , 1045-1047
- https://doi.org/10.1172/jci9872
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Replication-selective adenoviruses as oncolytic agentsJournal of Clinical Investigation, 2000
- The Hallmarks of CancerCell, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJournal of Clinical Investigation, 1999
- Long-term Continuous 5-Fluorouracil Infusion in Patients with Advanced Head and Neck CancerActa Oncologica, 1999
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agentsInternational Journal of Cancer, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990